Page 94 - 《中国药房》2025年23期
P. 94
系统评估不同抗凝剂(如肝素钠)的影响,也缺乏-20 ℃ transportation:an overview[J]. Diagnosis (Berl),2019,6
冻存或高温应激等极端温度条件下的稳定性验证数据。 (1):39-43.
后续研究会进一步扩大样品量,系统考察更多温度梯度 [ 9 ] LIPPI G,VON MEYER A,CADAMURO J,et al.
与抗凝条件的影响,并探索构建基于物联网技术的智能 PREDICT:a checklist for preventing preanalytical diag‐
nostic errors in clinical trials[J]. Clin Chem Lab Med,
化温度实时监控系统。这些改进有望推动形成更具普
2020,58(4):518-526.
适性的标准操作规范,为相关领域专业人员提供兼具科
[10] MURPHY R F,BALIS F M,POPLACK D G. Stability of
学性与实践指导意义的参考依据。
5-fluorouracil in whole blood and plasma[J]. Clin Chem,
综上,全血中的 5-FU 在室温条件下稳定性较差,
1987,33(12):2299-2300.
2~8 ℃冷藏时稳定性略有提升但仍会快速降解;添加 [11] LEE J J,BEUMER J H,CHU E. Therapeutic drug moni‐
1%体积比的稳定剂可显著延长其冷藏保存时间。本研 toring of 5-fluorouracil[J]. Cancer Chemother Pharmacol,
究制定了5-FU TDM临床采样转运标准化流程,创新性 2016,78(3):447-464.
地将稳定剂添加节点设置于样品接收环节(而非采血后立 [12] LI M,MINDT S,LÜCK A,et al. Drug monitoring detects
即添加),在保证样品分析质量的前提下,更贴合临床采 under- and overdosing in patients receiving 5-fluorouracil-
血的实际操作条件,显著提升了临床实际操作的可行性。 containing chemotherapy-results of a prospective,multi‐
致谢:感谢浙江迪赛思诊断技术有限公司提供的 center German observational study[J]. ESMO Open,
血浆稳定性数据支持。 2023,8(2):101201.
[13] 张娟,吴东媛,刘铎,等. 5-FU治疗药物监测现状及其与
利益冲突声明:本文作者与该公司无任何经济利益
结直肠癌化疗毒性相关性的研究进展[J]. 中国药房,
关联或潜在利益冲突。
2018,29(12):1724-1728.
参考文献
[14] 李然,焦园园,刘颖,等 . 1 例卡培他滨致严重不良反应
[ 1 ] GLEWIS S,MICHAEL M,GURNEY H,et al. Feasibility
患者的治疗药物监测[J]. 中国药物应用与监测,2015,12
and population exposure of 5-fluorouracil using therapeu‐
(6):354-356.
tic drug monitoring (PREDICT-5FU):a multicentre clini‐
[15] QIN W,WANG X X,CHEN W Q,et al. An in vitro ap‐
cal trial[J]. Br J Clin Pharmacol,2025,91(7):1965-1974.
proach to simulate the process of 5-fluorouracil degrada‐
[ 2 ] KALDATE R R,HAREGEWOIN A,GRIER C E,et al. tion with dihydropyrimidine dehydrogenase:the process
Modeling the 5-fluorouracil area under the curve versus in accordance to the first-order kinetic reaction[J]. Xenobio-
dose relationship to develop a pharmacokinetic dosing tica,2021,51(1):24-30.
algorithm for colorectal cancer patients receiving FOLFOX6 [16] RADOVANOVIC M,SCHNEIDER J J,MARTIN J H,
[J]. Oncologist,2012,17(3):296-302. et al. Comparison between a single- and a multi-point cali‐
[ 3 ] BEUMER J H,CHU E,ALLEGRA C,et al. Therapeutic bration method using LC-MS/MS for measurement of 5-
drug monitoring in oncology:international association of fluorouracil in human plasma[J]. J Mass Spectrom Adv
therapeutic drug monitoring and clinical toxicology re- Clin Lab,2024,33:31-37.
commendations for 5-fluorouracil therapy[J]. Clin Phar‐ [17] GURJAR M,PRIYAN K A,ASIA P,et al. Optimizing
macol Ther,2019,105(3):598-613. cancer patient care with a robust assay for 5-fluorouracil
[ 4 ] 佟志强,吴东媛,张娟,等. UPLC-MS/MS法同时测定人 quantification and in vitro stability in human blood for
血浆中 5-FU 及其代谢产物 5-FUH2的浓度及应用[J]. 中 therapeutic drug monitoring[J]. Pract Lab Med,2024,40:
国药房,2021,32(4):480-484. e00415.
[ 5 ] 涂碎萍,李获,陈岷,等. LC-MS测定结直肠癌患者血浆 [18] 范先煜,汪硕闻,范国荣. LC-MS/MS法同时检测人血浆
中 5-氟尿嘧啶浓度[J]. 实用药物与临床,2018,21(9): 中氟尿嘧啶、尿嘧啶和二氢尿嘧啶的浓度及其临床应用
1047-1051. [J]. 药学服务与研究,2021,21(1):12-18.
[ 6 ] 封敬颖,边静,崔毅轩,等. 中空纤维离心超滤结合高效 [19] ANDO M,WATANABE N,SEIKE R,et al. Quantifica‐
液相色谱法测定5-氟尿嘧啶的血药浓度[J]. 中国医院药 tion of gimeracil,tegafur,and 5-FU in human plasma via
学杂志,2021,41(13):1305-1308. LC-MS/MS with a simplified pretreatment using flow-
[ 7 ] PLEBANI M,SCOTT S,SIMUNDIC A M,et al. New in‐ through extraction[J]. J Chromatogr B Analyt Technol
sights in preanalytical quality[J]. Clin Chem Lab Med, Biomed Life Sci,2025,1251:124424.
2025,63(9):1682-1692. (收稿日期:2025-08-05 修回日期:2025-11-21)
[ 8 ] NYBO M,CADAMURO J,CORNES M P,et al. Sample (编辑:胡晓霖)
· 2968 · China Pharmacy 2025 Vol. 36 No. 23 中国药房 2025年第36卷第23期

